Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of sapanisertib alone or with MLN1117 versus everolimus in advanced or metastatic clear-cell renal cell carcinoma after VEGF-targeted therapy
2015-002133-22Phase 2Completed
- Sponsor
- Takeda
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Sapanisertib monotherapy, Sapanisertib + MLN1117 and Everolimus (3 arms). Primary endpoint: Progression-free survival. Started May 2016; status: completed.
02
Drugs
sapanisertibserabelisibeverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2015-002133-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002133-22.